Background
Cristina Adriana Popa
Heir to the Throne? Obinutuzumab in the ...

This week, NephJC will discuss whether obinutuzumab is ready to outperform tacrolimus in primary membranous nephropathy

Heir to the Throne? Obinutuzumab in the membranous nephropathy MAJESTY trial
Background
Pallavi Prasad
Is all kidney disease in Diabetics "Diabetic ...

In this edition of NephJC, we discuss the largest case series of kidney biopsies in patients with Diabetes.

Is all kidney disease in Diabetics "Diabetic Nephropathy"?
Cristina Adriana Popa
NephJC Internship 2026-2027

Introducing NephJC’s brand new editorial internship class of 2026-2027

NephJC Internship 2026-2027
Background
Cristina Adriana Popa
Making an IMPACT on BP: Why pills alone won't ...

This week we will discuss whether a bundled, team-based hypertension intervention- featuring intensive BP targets, home monitoring, health coaching, and audit feedback- can overcome poverty, clinical inertia, and fragmented care to improve blood pressure control in low-income patients receiving care at federally qualified health centers.

Making an IMPACT on BP: Why pills alone won't win the war
Background
Cristina Adriana Popa
Is TRPC6 inhibition for FSGS a trick or a treat?

This week, we will discuss a phase 2 trial of the TRPC6 inhibitor BI 764198 in FSGS—an early signal for a podocyte-targeted therapy showing proteinuria reduction but set against small numbers, heterogeneity, and methodological trade-offs that frame this as direction-finding rather than definitive evidence.

Is TRPC6 inhibition for FSGS a trick or a treat?

pregnancy

#TenTweetNephJC does CHAP

After CHIP we discussed CHAP. In case you missed it, we have you covered here: